Efficacy comparison between pemetrexed combined with cisplatin and docetaxel combined with cisplatin in treatment of non-small cell lung cancer
- VernacularTitle:培美曲塞联合顺铂与多西他赛联合顺铂治疗非小细胞肺癌的疗效对比
- Author:
Guoquan LU
;
Xiaohong ZHOU
;
Hong CHEN
;
Jianping TAN
- Publication Type:Journal Article
- Keywords:
pemetrexed;
non-small cell lung cancer;
docetaxel;
cisplatin
- From:
Chinese Journal of Biochemical Pharmaceutics
2015;(8):143-145
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare efficacy of pemetrexed (MTA) combined with cisplatin (DDP) and docetaxel (TXT) combined with DDP in treatment of non-small cell lung cancer (NSCLC).Methods 50 patients with NSCLC from May 1, 2013 to May 1, 2015 in the hospital were seleced and randomly divided into two groups:MTA group (n=25) were received MTA combined with DDP, and TXT group(n=25) were received TXT combined with DDP, for a course of twenty-one days.After treatment, the efficacy of two therapy as well as adverse reactions were compared.ResuIts After treatment, the soluble intercellular adhesion molecule 1 (sICAM-1) and soluble vasccular cell adhesion molecule 1 (sVCAM-1) levels in MTA group were significantly lower than those before treatment (P<0.05), but there were no statistical differences in TXT group, and the above two indicators in MTA group were lower than those in TXT group(P<0.05).There were no significant difference of total efficacy between MTA group and TXT group (20.00% vs.16.00%, χ2 =0.136,P>0.05).The adverse reaction of nausea and vomiting, anemia, low platelet count, neutropenia and alopecia in MTA group was lower than that in TXT group (40.00%vs.72.00%,χ2 =5.195,P<0.05).ConcIusion The efficacy of MTA combined with DDP and TXT combined with DDP in treatment of NSCLC is similar, but the adverse reactions of fomer one is lower.
